Silence Therapeutics (SLN) Coverage Initiated by Analysts at Peel Hunt
Analysts at Peel Hunt began coverage on shares of Silence Therapeutics (LON:SLN) in a note issued to investors on Thursday. The brokerage set a “buy” rating and a GBX 276 ($3.71) price target on the stock. Peel Hunt’s target price would suggest a potential upside of 40.10% from the company’s current price.
Shares of Silence Therapeutics (LON SLN) opened at GBX 197 ($2.65) on Thursday. Silence Therapeutics has a 12-month low of GBX 71.88 ($0.97) and a 12-month high of GBX 254.75 ($3.43).
Silence Therapeutics Company Profile
Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.